Gapping down
In reaction to earnings/guidance:
- PTON -32.9% (seeing a softer than anticipated start to DecQ), BLUE -24.6%, PBYI -23.5%, EBS -14.5%, TRHC -12.7%, AXNX -12.3%, CGNX -11.2% (also increases dividend), IRTC -9.4%, NVAX -9.2% (also completes rolling submission to WHO for listing of NVX-CoV2373), DKNG -8.6%, DVAX -8.5%, SWCH -7.7%, SLQT -7.2%, MITK -7.2%, PGNY -7.1% (also CEO to become Exec Chairman; names new CEO), TDC -6.8% (also announces collaboration with Amazon Web Services), REZI -6.1%, VIR -6.1%, APPN -5.9%, OLED -5.9%, MNDT -5.5%, FND -5.4%, BE -5%, ZGNX -5%, LTHM -4.9%, CVNA -4.9%, VLDR -4.8% (also names new CEO), UI -4.8%, MGA -4.6%, FSLR -4%, RGA -4%, SQ -3.6%, GSAT -3.6%, RKT -3.4%, AXON -2.7%, CGC -2.7%, CLNE -2.5%, WW -2.4%, BGS -2.3%, HMC -2.3%, GBT -2.2%, DNLI -2.2%, IOVA -2.1%, CMBM -2%, FATE -1.9%, GKOS -1.8%, AGO -1.7%, RUN -1.6%, ALTR -1.4%, TEN -1.4%, NPTN -1.3%, MTZ -1.2%, RDFN -1.1%, MDRX -1.1%, AGS -1.1%, MORF -1.1%, BEP -1.1%
Other news:
- DCPH -68.9% (top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK did not meet primary endpoint)
- EVAX -44.2% (pricies follow-on public offering of 3428571 ADSs at a public offering price of $7.00 per ADS)
- CALA -42.1% (to terminate its phase 2 KEAPSAKE clinical trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis)
- NRXP -31.7% (FDA declines to issue EUA for ZYESAMI for patients with Critical COVID-19 respiratory failure)
- EBS -14.5% (discloses it and US government mutually agreed to terminate the US government contract)
- MNKD -13.7% (provides Technosphere Insulin dose updates)
- MRK -9.8% (following news of Pfizer's COVID-19 oral antiviral treatment update)
- MRNA -8.2% (following news of Pfizer's COVID-19 oral antiviral treatment update)
- NVAX -7.8% (following news of Pfizer's COVID-19 oral antiviral treatment update)
- BNTX -7.6% (following news of Pfizer's COVID-19 oral antiviral treatment update)
- REGN -7% (files mixed securities shelf offering)
- ABUS -6.2% (files for $250 mln mixed securities shelf offering; also stock offering)
- MRUS -6.1% (prices offering of 3859650 shares of common stock at $28.50 per share)
- MOS -5.6% (files for mixed securities shelf offering)
- TRNO -3.6% (prices offering of 3.5 mln shares of common stock at $74.50 per share)
- FTCI -2.1% (awarded first solar project in Africa)
- CDAK -2.1% (files for $300 mln mixed securities shelf offering)
- SNCR -2% (will supply its personal cloud solution to Telkomsel Indonesia's largest mobile operator)
- FATE -1.9% (files for $350 mln offering relating to sales agreement; also files mixed securities shelf offering)
- NMM -1.3% (names new CFO and COO)
- XM -0.7% (prices offering of 23809524 shares of common stock at $42.00 per share)
Analyst comments:
- NKLA -4.7% (downgraded to Neutral from Buy at BTIG Research)
- PZZA -3.6% (downgraded to Hold from Buy at Deutsche Bank)
- NOMD -1.9% (downgraded to Neutral from Buy at Goldman)